Lifecore Biomedical Receives 'Hold' Rating from Analysts

Analysts see mixed outlook for the specialty biopharmaceutical company

Apr. 11, 2026 at 8:13am

Got story updates? Submit your updates here. ›

A close-up image of the intricate machinery and mechanisms inside a pharmaceutical manufacturing facility, captured in high-contrast black and white to convey the complex, industrial nature of biopharmaceutical production.The specialized equipment and processes behind Lifecore Biomedical's hyaluronic acid-based products are crucial to the company's operations and growth.Chaska Today

Lifecore Biomedical, Inc. (NASDAQ:LFCR) has received a consensus 'Hold' rating from the five analysts covering the firm, according to MarketBeat. One analyst has a 'Sell' recommendation, two have 'Hold' ratings, and two have 'Buy' recommendations, with an average 12-month price target of $5.50.

Why it matters

Lifecore Biomedical is a specialty biopharmaceutical company focused on developing and commercializing hyaluronic acid-based products. The mixed analyst ratings and price target suggest uncertainty around the company's near-term performance and growth prospects.

The details

The analysts' ratings come after Lifecore reported a Q1 earnings miss, with the company citing higher costs and expenses. However, the company's revenue of $35.75 million in the quarter met analyst expectations.

  • Lifecore reported Q1 2026 earnings on March 16, 2026.

The players

Lifecore Biomedical, Inc.

A publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota that focuses on the development, manufacture and commercialization of hyaluronic acid-based products.

Millennium Management LLC

A hedge fund that increased its stake in Lifecore Biomedical by 86.2% during the fourth quarter of 2025.

Got photos? Submit your photos here. ›

The takeaway

Lifecore Biomedical faces a mixed outlook from analysts, with concerns around its recent earnings miss and higher costs offsetting expectations for growth in its hyaluronic acid-based product portfolio. The company's ability to manage expenses and drive sales will be key factors in determining its near-term performance.